Clinical trials of a COVID-19 vaccine created by FMBA began in Russia

The Federal Biomedical Agency has received permission from the Ministry of Health to conduct the first and second phases of clinical trials of its coronavirus vaccine. About it reported to the press service of the agency.

“In June 2021, preclinical studies of the vaccine preparation were successfully completed, as a result of which its safety, immunogenicity and protectiveness were proved,” the FMBA press service said. Clinical trials of the drug will be conducted from July 19, 2021.

The ministry noted that the new vaccine is aimed at developing cellular immunity, and the conservative proteins of the coronavirus, the least susceptible to mutations, are used as a target.

Now in Russia, four drugs for COVID-19 are registered: vector vaccines “Sputnik V” and “Sputnik Light”, created by the National Research Center for Epidemiology and Microbiology. Gamalea, peptide vaccine “EpiVacCorona”, developed by the state scientific center of virology and biotechnology “Vector”, as well as whole-virion vaccine “KoviVac” of the Chumakov Center for Research and Development of Immunobiological Preparations.